A roadmap for antioxidant nanozymes in biomedical applications
Research
Background
Reactive oxygen species (ROS) are part of normal biology, contributing to cell signaling, immune defense, and tissue repair. Problems arise when their production persistently outpaces the body's ability to control them. The resulting oxidative stress can amplify inflammation and molecular damage in neurodegenerative disorders, cardiovascular disease, chronic inflammation, ischemia-reperfusion injury, and cancer.
Superoxide dismutase, catalase, and glutathione peroxidase are central to redox homeostasis. Yet their direct therapeutic use is limited by short circulation times, physiological inactivation, complex production, cost, potential immunogenicity, and limited accumulation at disease sites. Antioxidant nanozymes offer a materials-based way to mimic key enzyme reactions while tuning composition, structure, and surface chemistry.
Research Progress
Published in Research, Antioxidant Nanozymes: From Rational Design to Biomedical Applications takes a mechanism-first view of the field. The review traces how catalytic pathways inform active-site design, materials architecture, disease microenvironments, and the evidence required for translation.
The review centers on three enzyme-like functions. SOD-like nanozymes process superoxide through sequential electron-transfer steps. CAT-like nanozymes decompose hydrogen peroxide into water and oxygen. GPx-like nanozymes use glutathione to reduce peroxides. In each case, efficient catalysis depends on reversible redox cycling at active sites, which may allow nanozymes to regulate ROS without being consumed in a single reaction.
From this mechanistic foundation, the authors identify design variables that can be adjusted in practice: active-site identity and coordination, electronic structure, crystal defects, surface and interface chemistry, biomimetic microenvironments, and responsiveness to disease signals. The review also considers dual active sites, single-atom coordination, confined frameworks, cascade catalysis, and computational screening with density functional theory and machine learning.
Future Prospects
The review surveys studies in neuroprotection, anti-inflammatory therapy, cardiovascular protection, cancer-treatment support, tissue regeneration, and disease diagnosis. These applications require different modes of redox control. Neuroprotection may call for gentle, sustained ROS regulation, whereas inflammatory and ischemia-reperfusion settings may require local ROS removal together with changes in immune and tissue microenvironments. In tumor-related applications, the intended direction of ROS regulation depends on the therapeutic strategy.
Clinical translation will require more than high catalytic activity. Nanozymes must distinguish pathological ROS from physiological signaling ROS, behave predictably in protein-rich and immune-active environments, and undergo rigorous assessment of long-term safety and metabolism. The field also needs shared standards for activity and toxicology, stronger in vitro-to-in vivo correlations, reliable targeted delivery, scalable manufacturing, and appropriate regulatory strategies.
The authors suggest that future systems could sense local ROS levels, pH, or other disease cues and adjust their activity accordingly. For researchers, clinicians, and translational partners, the review offers a practical link between catalytic mechanisms, material-design choices, and disease-relevant evaluation.
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.